Sanford C. Bernstein set a €114.00 ($132.56) price objective on Merck KGaA (FRA:MRK) in a research report sent to investors on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other research analysts have also recently issued reports on the company. HSBC set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 15th. Morgan Stanley set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, September 10th. UBS Group set a €99.00 ($115.12) target price on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 8th. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the stock a buy rating in a research report on Friday, September 6th. Finally, DZ Bank reissued a buy rating on shares of Merck KGaA in a research report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have issued a buy rating to the stock. Merck KGaA has an average rating of Hold and an average price target of €101.33 ($117.83).
Shares of FRA:MRK opened at €103.90 ($120.81) on Wednesday. The stock’s 50-day simple moving average is €99.51 and its two-hundred day simple moving average is €95.58. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: Mutual Funds
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.